Nazli Dizman, MD, discusses the importance of the 3 main clauses of the language of respect guidelines in renal cell carcinoma.
Nazli Dizman, MD, hematology/oncology fellow at MD Anderson Cancer Center, discusses the potential impact that disrespectful language can have on patients with renal cell carcinoma (RCC).
Dizman and colleagues have done research on adherence to the American Society of Clinical Oncology (ASCO) Language of Respect Guidelines among patients with RCC and findings presented at the 2024 ASCO Genitourinary Annual Meeting looked at the adherence to these guidelines in regard to RCC abstracts which were presented at the 2023 ASCO Annual Meeting.
Here, Dizman highlights the importance of the 3 main clauses of the language of respect guidelines.
Transcription:
0:09 | The essence of our jobs as oncology providers is to really team up with our patients to help them go through these challenging situations. For oncologists, there are several ups and downs, and effective communication skills are very important. Patients would want to hear genuine advice that does not blame them or does not count them responsible for anything happening. This will be 1 of the most valuable things that the patients prioritize. If we do this well, we know that they thank us for doing that. Most of us would potentially achieve effective rapport with the patient after spending time in several visits, but it is challenging to do that on the podium or do that while writing papers.
1:12 | I think there is still room for improvement in the language we use in communications and in our presentations or our manuscripts or abstracts. I think our reports in kidney cancer, and we have 2 other reports, 1 in bladder cancer and 1 in prostate cancer, they all highlight the importance of building these skills. I think awareness and adherence to patient respectful language is a good step to help build that rapport for patients we are not seeing personally, and for the broader community of oncology, especially while they are going through challenging times.
Transcription created with AI and edited for clarity.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More